Grand Pharma entered into a product cooperation agreement with Pediatrix Therapeutics Technology (Shanghai) Co. Ltd.* (祐兒醫藥科技（上海）有限公司, Pediatrix Therapeutics) recently. We will acquire the exclusive commercialization rights in Mainland China through cooperative channels and the nonexclusive commercialization rights in Hong Kong Special Administrative Region for Neffy?, the world’s first adrenaline nasal spray for emergency treatment of type I allergic reactions (including severe allergic reactions) in adults and children weighing over 30kg (2mg specification) and children weighing 15-30kg (1mg specification). This collaboration is led by Grand Pharma (Beijing) Co., Ltd.* (遠大醫藥（北京）有限公司), a subsidiary of the Group, and plans to achieve localized production within 24 months after the product is approved.
Pediatrix Therapeutics’ core product, Neffy?, is the first non-injectable treatment product approved by the United States Food and Drug Administration (FDA) for the treatment of type I allergic reactions (including severe allergic reactions). It uses an innovative nasal spray delivery method.
Its pivotal clinical study results show that subjects treated with Neffy? or approved adrenaline injection products had comparable blood concentrations of a
